摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(3R)-1-[(1,1-二甲基乙氧基)羰基]-3-哌啶乙酸 | 912940-89-7

中文名称
(3R)-1-[(1,1-二甲基乙氧基)羰基]-3-哌啶乙酸
中文别名
(R)-N-BOC-2-(哌啶-3-YL)乙酸
英文名称
(R)-2-(1-(tert-butoxycarbonyl)piperidin-3-yl)acetic acid
英文别名
2-[(3R)-1-[(2-methylpropan-2-yl)oxycarbonyl]piperidin-3-yl]acetic acid
(3R)-1-[(1,1-二甲基乙氧基)羰基]-3-哌啶乙酸化学式
CAS
912940-89-7
化学式
C12H21NO4
mdl
——
分子量
243.303
InChiKey
QZYGREZDLJVVSV-SECBINFHSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    373.0±15.0 °C(Predicted)
  • 密度:
    1.121

计算性质

  • 辛醇/水分配系数(LogP):
    1.4
  • 重原子数:
    17
  • 可旋转键数:
    4
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.83
  • 拓扑面积:
    66.8
  • 氢给体数:
    1
  • 氢受体数:
    4

安全信息

  • 海关编码:
    2933399090

SDS

SDS:fdb23f7f0ff2cb7b8364506a5ca91dd3
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: (R)-(1-Boc-piperidin-3-yl)-acetic acid
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: (R)-(1-Boc-piperidin-3-yl)-acetic acid
CAS number: 912940-89-7

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C12H21NO4
Molecular weight: 243.3

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

  • 作为反应物:
    描述:
    (3R)-1-[(1,1-二甲基乙氧基)羰基]-3-哌啶乙酸吡啶盐酸N,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下, 以 1,4-二氧六环二氯甲烷N,N-二甲基甲酰胺 为溶剂, 反应 2.5h, 生成 (R)-N-(3,5-dichloro-4-(3-isopropyl-4-methoxyphenoxy)phenyl)-2-(1-(methylsulfonyl)piperidin-3-yl)acetamide
    参考文献:
    名称:
    [EN] AGONISTS OF ROR GAMMAt
    [FR] AGONISTES DE ROR GAMMAT
    摘要:
    本发明涉及公式(I)中所有取代基的化合物,如本文所定义,以及包括该发明化合物的药学上可接受的组合物,以及使用该组合物治疗各种疾病的方法。
    公开号:
    WO2021026179A1
点击查看最新优质反应信息

文献信息

  • MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS
    申请人:Combs Andrew Paul
    公开号:US20090286778A1
    公开(公告)日:2009-11-19
    The present invention relates to macrocyclic compounds of Formula I: or pharmaceutically acceptable salts thereof or quaternary ammonium salts thereof wherein constituent members are provided hereinwith, as well as their compositions and methods of use, which are JAK/ALK inhibitors useful in the treatment of JAK/ALK-associated diseases including, for example, inflammatory and autoimmune disorders, as well as cancer.
    本发明涉及以下化学式I的大环化合物: 或其药用可接受盐或季铵盐,其中所述成员在此提供,并且它们的组成物和使用方法,这些JAK/ALK抑制剂在治疗JAK/ALK相关疾病中有用,例如炎症和自身免疫性疾病以及癌症。
  • [EN] SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS<br/>[FR] AGONISTES DES RÉCEPTEURS SPHINGOSINE-1-PHOSPHATE
    申请人:BRISTOL MYERS SQUIBB CO
    公开号:WO2011017578A1
    公开(公告)日:2011-02-10
    Disclosed are compounds of Formula (I), or a stereoisomer or a pharmaceutically acceptable salt thereof, wherein: A is formula (II) Q is a substituted 5-membered monocyclic heteroaryl group; W is CH2, O, or NH; and R1, R2, R3, R4, R5, R6, m, n, t, and x are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.
    揭示了Formula (I)的化合物,或其立体异构体或药用可接受的盐,其中:A为Formula (II),Q为取代的5-成员单环杂芳基团;W为CH2、O或NH;而R1、R2、R3、R4、R5、R6、m、n、t和x在此处有定义。还揭示了将这些化合物用作G蛋白偶联受体S1P1的选择性激动剂的方法,以及包含这些化合物的药物组合物。这些化合物在治疗、预防或减缓多种治疗领域的疾病或紊乱方面具有用处,如自身免疫疾病和血管疾病。
  • [EN] IMMUNOPROTEASOME INHIBITORS<br/>[FR] INHIBITEURS D'IMMUNOPROTÉASOME
    申请人:PRINCIPIA BIOPHARMA INC
    公开号:WO2019099582A1
    公开(公告)日:2019-05-23
    Provided herein are compounds, such as a compound of Formula (I), or a pharmaceutically acceptable salt thereof, that are immunoproteasome (such as LMP2 and LMP7) inhibitors. The compounds described herein can be useful for the treatment of diseases treatable by inhibition of immunoproteasomes. Also provided herein are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    本文提供了化合物,例如式(I)的化合物,或其药用可接受的盐,这些化合物是免疫蛋白酶体(如LMP2和LMP7)抑制剂。本文描述的化合物可用于治疗通过抑制免疫蛋白酶体可治疗的疾病。本文还提供了含有这些化合物的药物组合物和制备这些化合物的方法。
  • SUBSTITUTED QUINOLONES III
    申请人:Fuerstner Chantal
    公开号:US20090181996A1
    公开(公告)日:2009-07-16
    The invention relates to substituted quinolones and to methods for their preparation as well as to their use for the production of medicaments for the treatment and/or prophylaxis of diseases, especially for use as antiviral agents, particularly against cytomegaloviruses.
    这项发明涉及替代喹诺酮及其制备方法,以及它们用于制备药物治疗和/或预防疾病的用途,特别是用作抗病毒剂,特别是针对巨细胞病毒。
  • [EN] COVALENT BTK INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS COVALENTS DE BTK ET LEURS UTILISATIONS
    申请人:X-CHEM INC
    公开号:WO2017190048A1
    公开(公告)日:2017-11-02
    The present invention features compounds having BTK inhibitory activity. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing various medical conditions, such as cardiovascular diseases, respiratory diseases, inflammation, and diabetes.
    本发明涉及具有BTK抑制活性的化合物。本发明的化合物,单独或与其他药用活性剂结合使用,可用于治疗或预防各种医疗状况,如心血管疾病、呼吸系统疾病、炎症和糖尿病。
查看更多